Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with Ibrutinib and Nivolumab in CLL and Richter Transformation
NCT04781855Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of ipilimumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and Richter syndrome (RS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose of Ipilimumab up to 2 years and Dose Limiting Toxicities at 21 days. Planned start Jul 2022; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT04781855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781855.